SPRING VALLEY, N.Y., May 30, 2006 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that its wholly-owned subsidiary, Kali Laboratories, Inc., has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for polyethylene glycol 3350 NF powder for oral solution, 17 grams/scoopful. Polyethylene glycol 3350 NF powder for oral solution is the generic version of Miralax(TM), which is marketed by Braintree Laboratories, Inc. and is indicated for the treatment of occasional constipation. Total annual U.S. sales of polyethylene glycol 3350 NF powder for oral solution exceed $150 million. Par will begin shipping the product immediately.

KANSAS CITY, M.O. -- May 17, 2006 -- The U.S. Food and Drug Administration (FDA) has approved Azilect(R) (rasagiline tablets), the first once-daily oral treatment for Parkinson's disease (PD).